Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Healthtrust
McKinsey
Boehringer Ingelheim
Harvard Business School
Covington

Generated: August 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,603,482

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,603,482
Title:Compositions and methods for cancer immunotherapy
Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
Inventor(s): Rossignol; Daniel P. (Ridgefield Park, NJ), Ishizaka; Sally T. (Weston, MA), Hawkins; Lynn D. (Andover, MA), Fields; Scott (Towaco, NJ)
Assignee: Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP)
Application Number:13/158,786
Patent Claims:1. A method for stimulating an immune response to a cancer antigen in a subject individual, the method comprising the steps of: administering to the individual one or more anti-cancer antibodies generated against said cancer antigen; and administering to the individual a compound of formula (I) ##STR00113## wherein: R.sup.1 is: (a) --C(O)--; (b) --C(O)--C.sub.1-14 alkyl-C(O)-- or --C(O)--C.sub.1-14 alkenyl-C(O)--; wherein the --C.sub.1-14 alkyl- or --C.sub.1-14 alkenyl- is optionally substituted with one or more substituents selected from the group consisting of hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkyldioxy, C.sub.1-5 alkylamino, carboxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 carbamoyl, C.sub.1-6 acylamino, and/or (aryl)C.sub.1-6 alkyl; and wherein the aryl moiety of the (aryl)C.sub.1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylamino, C.sub.1-6 alkoxyamino, C.sub.1-6 alkylamino-C.sub.1-6 alkoxy, --O--C.sub.1-6 alkylamino-C.sub.1-6 alkoxy, --O--C.sub.1-6 alkylamino-C(O)--C.sub.1-6 alkyl-C(O)OH, --O--C.sub.1-6 alkylamino-C(O)--C.sub.1-6 alkyl-C(O)--C.sub.1-6 alkyl, --O--C.sub.1-6 alkyl-NH--C.sub.1-6 alkyl-O--C.sub.1-6 alkyl, --O--C.sub.1-6 alkyl-NH--C(O)C.sub.1-6 alkyl-C(O)OH, and/or --O--C.sub.1-6 alkyl-NH--C(O)C.sub.1-6 alkyl-C(O)--C.sub.1-6 alkyl; (c) a C.sub.2 to C.sub.15 straight or branched chain alkyl group optionally substituted with one or more hydroxyl or alkoxy groups; or (d) --C(O)--C.sub.6-12 aryl-C(O)-- wherein the aryl is optionally substituted with one or more group selected from the group consisting of hydroxy, halo, nitro, amino, C.sub.1-6 alkyl and C.sub.1-6 alkoxy groups; a and b are each independently 0, 1, 2, 3 or 4; a' and b' are independently 2, 3, 4, 5, 6, 7 or 8; d and e are each independently 1, 2, 3, 4, 5 or 6; d' and e' are each independently 0, 1, 2, 3 or 4; d'' and e'' are each independently 0, 1, 2, 3 or 4; T is oxygen or sulfur; X.sup.1, X.sup.2, Y.sup.1 and Y.sup.2 are each independently null, oxygen, NH, --N(C(O)C.sub.1-4 alkyl)-, or --N(C.sub.1-4 alkyl)-; W.sup.1 and W.sup.2 are each independently selected from the group consisting of carbonyl, methylene, sulfone and sulfoxide; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are each independently: (a) C.sub.2 to C.sub.20 straight chain or branched chain alkyl, which is optionally substituted with one or more groups selected from the group consisting of oxo, halo, hydroxy and alkoxy groups; (b) C.sub.2 to C.sub.20 straight chain or branched chain alkenyl, which is optionally substituted with one or more groups selected from the group consisting of oxo, halo, hydroxy and alkoxy groups; (c) C.sub.2 to C.sub.20 straight chain or branched chain alkoxy, which is optionally substituted with one or more groups selected from the group consisting of oxo, halo, hydroxy and alkoxy groups; (d) --NH--C.sub.2-20 straight chain or branched chain alkyl, wherein the alkyl group is optionally substituted with one or more groups selected from the group consisting of oxo, halo, hydroxy and alkoxy groups; (e) --C(O)--C.sub.2-20 straight chain or branched chain alkyl or alkenyl, wherein the alkyl or alkenyl is optionally substituted with one or more groups selected from the group consisting of oxo, halo, hydroxy and alkoxy groups; ##STR00114## Z is O or NH; and M and N are each independently C.sub.2 to C.sub.20 straight chain or branched chain alkyl, alkenyl, alkoxy, acyloxy, alkylamino, or acylamino; or ##STR00115## R.sup.8 is C.sub.1-6 straight or branched chain alkyl or C.sub.2-6 straight or branched chain alkenyl or alkynyl; R.sup.9 and R.sup.10 are independently selected from the group consisting of (i) C.sub.1 to C.sub.20 straight chain or branched chain alkyl, which is optionally substituted with one or more groups selected from the group consisting of halo, oxo, hydroxy and alkoxy; and (ii) C.sub.2 to C.sub.20 straight chain or branched chain alkenyl or alkynyl which is optionally substituted with one or more groups selected from the group consisting of halo, oxo, hydroxy and alkoxy; G.sup.1, G.sup.2, G.sup.3, G.sup.4 and G.sup.5 are each independently oxygen, methylene, --NH--, thiol, --N(C.sub.1-4alkyl)-, --N[C(O)--C.sub.1-4 alkyl]-, --NH--C(O)--, --NH--SO.sub.2--, --C(O)--O--, --C(O)--NH--, --O--C(O)--, --O--C(O)NH--, --O--C(O)O--, --NH--C(O)--NH--, --C(O)NH--, --C(O)N(C.sub.1-4 alkyl), aryl, and --S(O).sub.n--, wherein n is 0, 1, or 2; or G.sup.1R.sup.2, G.sup.2R.sup.4, G.sup.3R.sup.5 and/or G.sup.4R.sup.7 may together be a hydrogen atom or hydroxyl; Z.sup.1 and Z.sup.2 are each independently selected from the group consisting of --OP(O)(OH).sub.2, --P(O)(OH).sub.2, --OP(O)(OR.sup.8)(OH), where R.sup.8 is a C.sub.1-4 alkyl, --OS(O).sub.2OH, --S(O).sub.2OH--, --CO.sub.2H, --OB(OH).sub.2, --OH, --CH.sub.3, --NH.sub.2, and --N(R.sup.9).sub.2, where R.sup.9 is a C.sub.1-4 alkyl; R.sup.12 is H or a C.sub.1-4 straight or branched alkyl; and M is independently selected from a hydrogen atom and a pharmaceutically acceptable cation; and/or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, amorphous solid thereof, or any combination thereof; wherein the one or more anti-cancer antibodies is selected from the group consisting of trastuzumab, bevacizumab, rituximab, pertuzumab, cetuximab, IMC-1C11, tositumomab, ibirtumomab tiuxetan, EMD 7200, SGN-30, SGN-15, SGN-40, SGN-35, and SGN-17/19, and the compound of formula (I) is ER 804057 and/or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or amorphous solid thereof.

2. The method of claim 1, wherein the one or more anti-cancer antibodies and the compound of formula (I) are administered at about the same time.

3. The method of claim 1, wherein the one or more anti-cancer antibodies and the compound of formula (I) are administered separately.

4. The method of claim 3, wherein the one or more anti-cancer antibodies and the compound of formula (I) are administered in combination with cancer therapies.

5. The method of claim 4, wherein the cancer therapy is dendritic cell therapy, chemokines, cytokines, tumor necrosis factors, TNF-.alpha., chemotherapeutic agents, adenosine analogs, cladribine, pentostatin, alkyl sulfanates, busulfan, anti-tumoral antibiotics, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, mitomycin, aziridines, thiotepa, camptothecin analogs, irinotecan, topotecan, cryptophycins, cryptophycin 52, cryptophicin 1, dolastatins, dolastatin 10, dolastatin 15, enedyine anticancer drugs, esperamicin, calicheamicin, dynemicin, neocarzinostatin, neocarzinostatin chromophore, kedarcidin, kedarcidin chromophore, C-1027 chromophore, epipodophyllotoxins, etoposide, teniposide, folate analogs, methotrexate, maytansinoids, maytansinol, maytansinol analogues, microtubule agents, docetaxel, paclitaxel, vinblastine, vincristine, vinorelbine, nitrogen mustards, chlorambucil, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, nitrosoureas, carmustine, lamustine, streptoxacin, nonclassic alkylators, altretamine, dacarbazine, procarbazine, temozolamide, platinum complexes, carboplatin, cisplatin, purine analogs, fludarabine, mercaptopurine, thioguanine, pyrimidine analogs, capecitabine, cytarabine, depocyt, floxuridine, fluorouracil, gemcitabine, substituted ureas, hydroxyurea, anti-angiogenic agents, canstatin, troponin I, biologic agents, ZD 1839, virulizin, interferon, antibodies and fragments thereof, anti EGFR, anti-HER-2/neu, anti-KDR, IMC-C225, anti-emetics, lorazepam, metroclopramide, domperidone, epithelial growth factor inhibitors, transforming growth factor beta 1, anti-mucositic agents, dyclonine, lignocaine, azelastine, glutamine, corticoid steroids, allopurinol, anti-osteoclastic agents, bisphosphonates, etidronate, pamidronate, ibandronate, osteoprotegerin, hormone regulating agents, anti-androgens, LHRH agonists, anastrozole, tamoxifen, hematopoietic growth factors, anti-toxicity agents, amifostine and mixtures of two or more thereof.

6. The method of claim 1, wherein the one or more anti-cancer antibodies and the compound of formula (I) are administered to a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer.

7. The method of claim 6, wherein the one or more anti-cancer antibodies and the compound of formula (I) are administered therapeutically in combination with a surgical procedure to remove or reduce the size of a cancer tumor, radiation therapy, chemotherapy, and/or ablation therapy.

8. The method of claim 6, wherein the one or more anti-cancer antibodies and the compound of formula (I) are administered therapeutically to stabilize a tumor by preventing or slowing the growth of the existing cancer, to prevent the spread of a tumor or of metastases, to reduce the tumor size, to prevent the recurrence of treated cancer, or to eliminate cancer cells not killed by earlier treatments.

9. The method of claim 1, wherein the one or more anti-cancer antibodies and the compound of formula (I) are administered prophylactically to the subject individual to prevent or delay the development of cancer.

10. The method of claim 1, further comprising administering an immunostimulatory compound.

11. The method of claim 10, wherein said immunostimulatory compound is a toll like receptor (TLR) agonist, TLR4, TLR7, TLR9, N-acetylmuramyl-L-alanine-D-isoglutamine (MDP), lipopolysaccharides (LPS), genetically modified and/or degraded LPS, alum, glucan, colony stimulating factors, EPO, GM-CSF, G-CSF, M-CSF, pegylated G-CSF, SCF, IL-3, IL6, PIXY 321, interferons, .gamma.-interferon, .alpha.-interferon, interleukins, IL-2, IL-7, IL-12, IL-15, IL-18, MHC Class II binding peptides, saponins, QS2I, unmethylated CpG sequences, I-methyl tryptophan, arginase inhibitors, cyclophosphamide, or antibodies that block immunosuppressive functions, anti-CTLA4 antibodies, or mixtures of two or more thereof.

12. The method of claim 1, wherein the pharmaceutically acceptable salt of ER 804057 is E6020: ##STR00116##

Details for Patent 8,603,482

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP) 2025-04-26 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP) 2025-04-26 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP) 2025-04-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP) 2025-04-26 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP) 2025-04-26 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Try a Free Trial Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP) 2025-04-26 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,603,482

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2006116423 Nov 02, 2006
World Intellectual Property Organization (WIPO) 2006116423 Oct 09, 2008
United States of America 2007020232 Jan 25, 2007
United States of America 2007292418 Dec 20, 2007
United States of America 2011243935 Oct 06, 2011
United States of America 2011250171 Oct 13, 2011
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Queensland Health
Federal Trade Commission
US Army
Medtronic
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.